Sign In
Buy LIVN
$80.14
-0.91 (-1.12%)
At Close: Jul 31, 2026
Should Value Investors Buy LivaNova (LIVN) Stock?
10:41am, Tuesday, 30'th Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
LivaNova PLC (LIVN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:00pm, Wednesday, 10'th Sep 2025
LivaNova PLC (NASDAQ:LIVN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Fi
LivaNova PLC (LIVN) Soars to 52-Week High, Time to Cash Out?
05:35pm, Monday, 08'th Sep 2025
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LivaNova Appoints Donald Zurbay as a New Director
09:00am, Thursday, 04'th Sep 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of
LivaNova to Host Investor Day on November 12, 2025
09:00am, Monday, 25'th Aug 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
09:00am, Friday, 22'nd Aug 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex
LivaNova Launches Essenz Perfusion System in China
09:00am, Monday, 18'th Aug 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusi
LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript
11:18pm, Wednesday, 06'th Aug 2025
LivaNova PLC (NASDAQ:LIVN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Briana Got
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
08:11am, Wednesday, 06'th Aug 2025
LivaNova (LIVN) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.93 per share a year ago.
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
06:00am, Wednesday, 06'th Aug 2025
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the second quarter ended June 30, 2025, and raised full-year 2025 guidance.
LivaNova to Announce Second-Quarter 2025 Results
09:00am, Wednesday, 09'th Jul 2025
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug
LivaNova: The Sell-Off Is Excessive Here
01:34pm, Monday, 07'th Jul 2025
LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansio
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.
LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.
